WITHDRAWN: TRPM3 antagonist Ononetin exerts anti-cancer effects on non-small cell lung cancer (NSCLC) by suppressing TGF-β signaling

Xuan Zhang,Fei Chen,Chen Qian,Bai Lu
DOI: https://doi.org/10.1016/j.bbrc.2022.04.136
IF: 3.1
2022-05-01
Biochemical and Biophysical Research Communications
Abstract:Non-small cell lung cancer (NSCLC) is the most common histological type of lung cancer with limited therapies due to the poor understanding of its pathogenesis. Transient receptor potential melastatin-subfamily member 3 (TRPM3) is a member of the melastatin-like subfamily of TRP channels that conduct Ca2+ and Zn2+ ions, and has been shown to be involved in tumor growth. But its expression status and regulatory function in NSCLC are still unclear. In the study, we for the first time identified significant elevation of TRPM3 in NSCLC cell lines and tumor tissues, and its high expression predicted poor prognosis in patients with NSCLC. We subsequently found that Ononetin (Onon), as an antagonist of TRPM3, markedly reduced TRPM3 expression in NSCLC cells and markedly reduced the proliferation of NSCLC cells via a dose-dependent manner. Moreover, apoptosis was strongly induced by Onon by improving Casapse-3 activation. Transwell assays further showed that the migrative and invasive capacity of NSCLC cells was markedly restrained in NSCLC cells upon Onon exposure. RNA sequencing analysis was conducted to investigate the molecular mechanism revealing the anti-cancer effects of Onon on NSCLC and we notably found that Onon inhibited the transforming growth factor β (TGF-β) signaling pathway, accompanied by restrained expression of phosphorylated Smad2/3. Surprisingly, human recombinant TGF-β1 addition considerably abrogated the inhibitory role of Onon on NSCLC cell proliferation and the abnormal expression of epithelial-mesenchymal transition (EMT) hallmarks. Furthermore, in vivo studies using the xenograft mouse model confirmed that Onon administration strongly and dose-dependently reduced the tumor growth with undetectable toxicity. Together, all our findings demonstrated that TRPM3 is a biomarker to predict NSCLC progression, and its suppression by Onon may be a promising therapeutic strategy for NSCLC treatment.
biochemistry & molecular biology,biophysics
What problem does this paper attempt to address?